5-(4-Hydroxy-2,3,5-trimethylbenzylidene) thiazolidine-2,4-dione attenuates atherosclerosis possibly by reducing monocyte recruitment to the lesion
Experimental & Molecular Medicine
; : 471-478, 2011.
Article
em En
| WPRIM
| ID: wpr-210394
Biblioteca responsável:
WPRO
ABSTRACT
A variety of benzylidenethiazole analogs have been demonstrated to inhibit 5-lipoxygenase (5-LOX). Here we report the anti-atherogenic potential of 5-(4-hydroxy-2,3,5-trimethylbenzylidene) thiazolidin-2,4-dione (HMB-TZD), a benzylidenethiazole analog, and its potential mechanism of action in LDL receptor-deficient (Ldlr-/-) mice. HMB-TZD Treatment reduced leukotriene B4 (LTB4) production significantly in RAW264.7 macrophages and SVEC4-10 endothelial cells. Macrophages or endothelial cells pre-incubated with HMB-TZD for 2 h and then stimulated with lipopolysaccharide or tumor necrosis factor-alpha (TNF-alpha) displayed reduced cytokine production. Also, HMB-TZD reduced cell migration and adhesion in accordance with decreased proinflammatory molecule production in vitro and ex vivo. HMB-TZD treatment of 8-week-old male Ldlr-/- mice resulted in significantly reduced atherosclerotic lesions without a change to plasma lipid profiles. Moreover, aortic expression of pro-atherogenic molecules involved in the recruitment of monocytes to the aortic wall, including TNF-alpha , MCP-1, and VCAM-1, was downregulated. HMB-TZD also reduced macrophage infiltration into atherosclerotic lesions. In conclusion, HMB-TZD ameliorates atherosclerotic lesion formation possibly by reducing the expression of proinflammatory molecules and monocyte/macrophage recruitment to the lesion. These results suggest that HMB-TZD, and benzylidenethiazole analogs in general, may have therapeutic potential as treatments for atherosclerosis.
Palavras-chave
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Ensaio de Imunoadsorção Enzimática
/
Receptores de LDL
/
Monócitos
/
Dinoprostona
/
Distribuição Aleatória
/
Adesão Celular
/
Linhagem Celular
/
Movimento Celular
/
Fator de Necrose Tumoral alfa
/
Leucotrieno B4
Tipo de estudo:
Clinical_trials
Limite:
Animals
/
Humans
/
Male
Idioma:
En
Revista:
Experimental & Molecular Medicine
Ano de publicação:
2011
Tipo de documento:
Article